Download Enhancing Drug Bioavailability by Overcoming Intestinal

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Enhancing Drug Bioavailability by
Overcoming Intestinal Metabolism
Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D
Professor of Pharmaceutics
Department of Pharmaceutics
KLE University, Belgaum, India
E-mail: [email protected]
Cell No: 00919742431000
INTRODUCTION
• Drugs may be given in a number of ways
• Oral administration is the most common and
the easiest way to give a drug
• The amount of drug reaching the general
circulation will depend on a number of factors
• The proportion of drug that reaches the target
organs and tissues, which is expressed as a %
of the dose administered.
03/03/2010
BIOBIO-2010, Hyderabad
2
Intestinal Absorption of Oral Drugs
Passive Diffusion
• Most approved oral drugs
03/03/2010
Active Transport
• Nutrients (small peptides, amino acids,
vitamins, fatty acids, etc.)
• Selected drugs: valacyclovir, ACE inhibitors
cephalosporins, pravastatin, etc.
BIOBIO-2010, Hyderabad
3
Drug Absorption
• The drug is absorbed from the GI tract and
passes via the portal vein into the liver where
some drugs are metabolized
• Sometimes the result of first pass metabolism
means that only a proportion of the drug
reaches the circulation
• First pass metabolism can occur in the gut and
liver
03/03/2010
BIOBIO-2010, Hyderabad
4
Drug Absorption
• Absorption is the process by which a drug
enters the bloodstream without being
chemically altered
or
The movement of a drug from its site of
application into the blood or lymphatic
system
03/03/2010
BIOBIO-2010, Hyderabad
5
Drug Absorption
• Factors which influence the rate of
absorption
– types of transport
– the physicochemical properties of the drug
– protein binding
– routes of administration
– dosage forms
– circulation at the site of absorption
– concentration of the drug
03/03/2010
BIOBIO-2010, Hyderabad
6
Drug Absorption
• The rate at which a drug reaches it site of
action depends on:
– Absorption - involves the passage of the drug
from its site of administration into the blood
– Distribution - involves the delivery of the drug
to the tissues
03/03/2010
BIOBIO-2010, Hyderabad
7
Drug Absorption
• Mechanisms of solute transport across
membranes
– passive diffusion
– filtration and bulk flow
– endocytosis
– ion-pairing
– active transport
Drug Absorption animaton
03/03/2010
BIOBIO-2010, Hyderabad
8
03/03/2010
BIOBIO-2010, Hyderabad
9
Bioavailability
Definition: the fraction of the administered
dose reaching the systemic circulation
for i.v.: 100%
for non i.v.: ranges from 0 to 100%
e.g. lidocaine bioavailability 35% due to
destruction in gastric acid and liver metabolism
First Pass Effect
03/03/2010
BIOBIO-2010, Hyderabad
10
Bioavailability
Destroyed
in gut
Not
absorbed
Destroyed
by gut wall
to
systemic
circulation
Dose
03/03/2010
Destroyed
by liver
BIOBIO-2010, Hyderabad
11
The enterohepatic shunt
Drug
Liver
Bile formation
Bile
duct
Hydrolysis by
beta glucuronidase
Biotransformation;
glucuronide produced
gall bladder
Portal circulation
Gut
03/03/2010
BIOBIO-2010, Hyderabad
12
First-pass Effect
03/03/2010
BIOBIO-2010, Hyderabad
13
Bioavailability
=
(AUC)o
(AUC)iv
Plasma concentration
i.v. route
oral route
Time (hours)
03/03/2010
BIOBIO-2010, Hyderabad
14
Enzymatic status
• Luminal enzymes of the small intestine
- Pepsin is the primary enzyme found in gastric fluid.
- Other enzymes such as lipases, amylases and
peptides are secreted into the small intestine via the
pancreas in response to ingestion of food.
- Pepsins and proteases are responsible for the
breakdown of protein and peptide drugs in the
lumen.
- Drugs which resemble nutrients such as fatty acids
and nucleotides are susceptible to enzymatic attack.
03/03/2010
BIOBIO-2010, Hyderabad
15
Enzymatic status
• Colon
- Presence of bacterial enzymes in the colonic region
of the gastrointestinal tract, which digest material
not yet digested in the small intestine.
03/03/2010
BIOBIO-2010, Hyderabad
16
First-pass Effect
• The first-pass effect is the term used for the
hepatic metabolism of a pharmacological
agent when it is absorbed from the gut and
delivered to the liver via the portal circulation.
• The greater the first-pass effect, the less the
agent will reach the systemic circulation when
the agent is administered orally
03/03/2010
BIOBIO-2010, Hyderabad
17
First-pass Effect cont.
Magnitude of first pass hepatic effect:
Extraction ratio (ER)
ER = CL liver / Q ; where Q is hepatic blood
flow (usually about 90 L per hour).
Systemic drug bioavailability (F) may be
determined from the extent of absorption (f)
and the extraction ratio (ER):
F = f x (1 -ER)
03/03/2010
BIOBIO-2010, Hyderabad
18
Bypassing First Pass Metabolism
• Two ways to bypass first pass metabolism
involve giving the drug by sublingual and
buccal routes
• The drugs are absorbed by the oral mucosa in
both methods
• In sublingual administration the drug is put
under the tongue where it dissolves in salivary
secretions
03/03/2010
BIOBIO-2010, Hyderabad
19
Bypassing First Pass Metabolism
• Nitroglycerine is administered in this way
• In buccal administration the drug is placed
between the teeth and the mucous
membrane of the cheek
• Sublingual and buccal methods both avoid
destruction by the GI fluids and first pass
effect of the liver
03/03/2010
BIOBIO-2010, Hyderabad
20
Improving oral Bioavailability
• Particle Size Reduction
- Jet-milling, high energy ball milling
- Spray drying
- Super critical fluid extraction
- High supersaturation crystallization
• Solid Form Thermodynamics
- Amorphous
- Salts
- High Free Energy Polymorphs
• Improve Solubility
03/03/2010
BIOBIO-2010, Hyderabad
21
Attempted oral delivery systems
• Enzyme inhibition
- Difficult to target large variety of enzymes
- Interferes with natural metabolism
• Permeation enhancement
- Leads with non-specific paracellular transport
• Enteric coatings
- pH dependent solubility
- Maintain integrity through stomach, degrade in
intestine
- Modest success, but
still very low transport
03/03/2010
BIOBIO-2010, Hyderabad
22
Complexation hydrogels
• Poly(methacrylic acid-g-ethylene glycol), P(MAA-g-EG)
– MAA backbone grafted with terminally functional PEG chains
– Forms a water swollen, cross-linked polymer network
– Exhibits environmentally responsive pH dependent swelling
PMAA
CH3
CH3
H3C
CH3
H3C
CH3
O
O
O
H
H3C
O
O
O
-
O
O
H
O
O
O
High pH
pKa ~ 4.8
Low pH
Insulin
-
H
O
PEG
03/03/2010
BIOBIO-2010, Hyderabad
23
Approach
• Improve bioavailability of the oral delivery
system by modifying the network of the
P(MAA-g-EG) hydrogel and combining it with
chemically modified insulin species
• Insulin modification:
- PEGylated insulin can resist enzymatic attack
- Use Vitamin B12 to enhance transport across
intestinal wall
03/03/2010
BIOBIO-2010, Hyderabad
24
Insulin conjugation
• PEGylation: Covalent attachment of PEG to a protein
– Reduces enzymatic degradation of protein
– Increases circulation time
– Increases solubility of protein
• Would help overcome enzymatic barrier in intestine
• May enhance interaction between hydrogel and insulin
• PEG could be used as a linking agent for Vitamin B12
• Vitamin B12 is actively transported across epithelial cells
• May provide pathway to overcome physical barrier in the
intestines
03/03/2010
BIOBIO-2010, Hyderabad
25
Summary of Polymers used in pharmaceutical
formulations as coating materials.
Polymer
Trade name
Application
Shellac
EmCoat 120 N
Marcoat 125

Cellulose acetate
Aquacoat CPD®
Sepifilm™ LP
Klucel®
Aquacoat® ECD
Metolose®

Polyvinylacetate phthalate
Sureteric®

Methacrylate
Eudragit®

03/03/2010
Enteric Coatings
 Taste/Odor Masking
Enteric Coatings
 Taste masking
 Sustained release coating
 Sub coat moisture and barrier
Sealant pellet coating
Enteric Coatings
Enteric Coatings
 Sustained Release Coatings
 Taste Masking
 Moisture protection
BIOBIO-2010, Hyderabad Rapidly disintegrating Films
26
03/03/2010
BIOBIO-2010, Hyderabad
27
Anatomical Considerations
Gut Lumen
Portal Vein
Liver
Gut Wall
Systemic
Circulation
Metabolism
Metabolism
Release + Dissolution
Permeation
Elimination
Absorption
Bioavailability
03/03/2010
BIOBIO-2010, Hyderabad
28
Gabapentin Has a Limited GI Absorption
Window
Limited Capacity
Absorption Window
Stomach
1 to 6 hours
Small Intestine
2 to 4 hours
Colon
8 to 18 hours
Transit Time in Humans
• Saturable uptake – exposure not proportional to dose
• Variable capacity/transit times - inter-subject variability in PK
• No colonic absorption - SR formulation not possible
03/03/2010
BIOBIO-2010, Hyderabad
29
Overcoming a Limited Absorption
Window
Modify the drug for recognition by high capacity
transporters located throughout the intestine:
High Capacity Transporter
Stomach
1 to 6 hours
1.
2.
3.
4.
03/03/2010
Small Intestine
2 to 4 hours
Colon
8 to 18 hours
Increased bioavailability
Greater dose proportionality
Lower inter-patient variability
Reduced dosing frequency (sustained release)
BIOBIO-2010, Hyderabad
30
THANK YOU
03/03/2010
BIOBIO-2010, Hyderabad
31